Test Catalog

Test ID: DESG3    
Desmoglein 3 (DSG3) Immunostain, Technical Component Only

Useful For Suggests clinical disorders or settings where the test may be helpful

Classification of squamous cell carcinomas

Testing Algorithm Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Desmoglein 3 (DSG3) is a calcium-binding transmembrane glycoprotein component of desmosomes in vertebrate epithelial cells. Currently, three desmoglein subfamily members have been identified and all are members of the cadherin cell adhesion molecule superfamily. Positivity for DSG3 in a non-small cell lung carcinoma supports a diagnosis of squamous cell carcinoma.

Interpretation Provides information to assist in interpretation of the test results

This test does not includes pathologist interpretation; only technical performance of the stain. If an interpretation is required, order PATHC / Pathology Consultation for a full diagnostic evaluation or second opinion of the case.


The positive and negative controls are verified as showing appropriate immunoreactivity and documentation is retained at Mayo Clinic Rochester. If a control tissue is not included on the slide, a scanned image of the relevant quality control tissue is available upon request, call 855-516-8404.


Interpretation of this test should be performed in the context of the patient's clinical history and other diagnostic tests by a qualified pathologist.

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

Age of a cut paraffin section can affect immunoreactivity. Stability thresholds vary widely among published literature and are antigen-dependent. Best practice is for paraffin sections to be cut fresh.

Clinical Reference Recommendations for in-depth reading of a clinical nature

1. Funahashi SI, Kawai S, Fujii E, et al: Generation of an anti-desmoglein 3 antibody without pathogenic activity of pemphigus vulgaris for therapeutic application to squamous cell carcinoma. J Biochem. 2018 Dec;164(6):471-481. doi: 10.1093/jb/mvy074

2. Xiao J, Lu X, Chen X, et al: Eight potential biomarkers for distinguishing between lung adenocarcinoma and squamous cell carcinoma. Oncotarget. 2017 Sep 22;8(42):71759-71771. doi: 10.18632/oncotarget.17606

3. Brown L, Wan H: Desmoglein 3: a help or a hindrance in cancer progression? Cancers (Basel). 2015 Mar;7(1):266-286. doi: 10.3390/cancers7010266